Participated · Series A · May 2024

Amae Health is a San-Francisco–based Public Benefit Corporation focused on treating severe mental illness (SMI) through a combination of compassionate, team-based outpatient care and an AI-powered precision-medicine platform built on Palantir Foundry. Its clinics, first launched in Los Angeles in 2022, partner with leading health systems such as NewYork-Presbyterian, Cedars-Sinai, and Stanford Health Care to deliver coordinated treatment from psychiatrists, therapists, primary-care providers, dietitians, and social-services specialists. The company reports strong clinical outcomes, including reducing 30-day hospital readmissions to under 4% versus a 23% national average, improving measurement-based scores by up to 76% in mania, and maintaining a Net Promoter Score of 90. Key platform features—Patient-at-a-Glance, Point of Care Assistant, and Symptomology Phenotyping—help clinicians tailor interventions and monitor progress. Amae plans to use new capital to expand clinics nationwide, advance its AI tools, and support research into schizophrenia, bipolar disorder, and treatment-resistant depression through the newly formed Amae Institute. To date, the company has raised more than $50 million in funding, underscoring investor confidence in its integrated model and long-term goal of achieving five-year remission cures.

Participated · Series A · Aug 2023

KetoSwiss develops products aimed at improving brain energetics, a common denominator in many neurological and psychiatric diseases. Its first flagship medical food for migraine, MigraKet by Brain Ritual, pairs ketone bodies with micronutrients essential for brain energy metabolism. MigraKet is clinically tested, patent-protected, and is planned to enter the U.S. market at the end of 2023. The company is led by CEO and Founder Dr. Elena Gross and is based in Basel, Switzerland. KetoSwiss raised $4.8M in the second closing of a Pre-Series A financing and will use the funds to expand R&D and clinical development efforts.